Psychedelics
December 09, 2020 00:05 ET | Source: Pure Extracts Technologies Corp. VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), is a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector. The Company is pleased to announce that it has signed […]
Entheon Biomedical Corp. (CSE: “ENBI”) (FSE: “1XU1”) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the “Agreement”) with Psygen Labs Inc. (“Psygen”). Under the terms of the Agreement, Psygen will supply Entheon with non-GMP and GMP (good manufacturing practice) quality […]
PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson’s Disease
PharmaTher Inc., (“PharmaTher”), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that it has filed its pre-Investigational New Drug (“pre-IND”) meeting request and complete pre-IND briefing documents with the U.S. Food and […]
Mind Cure Announces its Research Program with Psychedelic Compounds
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (DTC: MCURF) (“Mind Cure”) is pleased today to announce its translational research program, with an initial focus on psilocybin, ketamine and ibogaine. These three psychedelic compounds have demonstrated safety profiles with proven efficacy but have not been optimized for medical use. This research program will […]
Havn Life Sciences to Supply Psychedelic Compounds to Clinical Studies Focused on Veterans and PTSD
Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (“Havn Life”), a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind, is pleased to announce it has signed a Memorandum of Agreement (“MOA”) with the international […]
Psyched Wellness Ltd. Adds Aaron Slater to the Advisory Board
Psyched Wellness Ltd. (CSE:PSYC) (OTCQB: DCNPF) (formerly Duncan Park Holdings Corporation) (“Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that Aaron Slater has joined the advisory board of the Company to work with the team on exploring new markets for its products […]
Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms
Mydecine completes harvest and is preparing to export 20 kilograms of psilocybin mushrooms from Jamaica to Canada for increased global supply scale of cGMP nature-sourced psilocybin DENVER, Dec. 08, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance […]
3 Ways to Invest in Psychedelic IP
The psychedelics industry has experienced a renaissance over the past two years with the launch of the Johns Hopkins Center for Psychedelic Research and a billion-dollar IPO. While there are many ways to capitalize on the industry, intellectual property will play a key role in both protecting assets and becoming a potential source of revenue. […]
Numinus Wellness Inc. Announces $10 Million Bought Deal Public Offering
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. and Eight Capital (the “Underwriters”). The Underwriters have agreed to […]
Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor
Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of […]
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: DCNPF) (FSE: 5U9) (formerly Duncan Park Holdings Corporation) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to provide the highlights from the toxicology assessment conducted by KGK Sciences (the “Toxicology Assessment“), a Canadian contract research […]
Cybin to host conference call today, December 7, 2020, at 5:00 p.m. ET Transaction adds extensive intellectual property portfolio and product pipeline to potentially diversify Cybin’s programs and includes multiple additional indications. Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic regimens supported by six patent applications. Adelia contributes an […]
Nova Mentis Appoints Dr. Marvin S. Hausman as Chairman of Scientific Advisory Board
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that it has appointed Dr. Marvin S. Hausman, MD as Chairman of its Scientific Advisory Board, effective immediately. Dr. Hausman is the Chief Medical Officer of Pilz Bioscience Corp., a wholly-owned subsidiary of NOVA and is […]
PsyBio Therapeutics, Inc. (“PsyBio”) and Leo Acquisitions Corp. (NEX: LEQ.H) (“Leo”) are pleased to announce the closing of the previously announced brokered private placement (the “Financing”) of subscription receipts (the “Subscription Receipts”) of PsyBio Therapeutics Financing Inc. (“Finco”), a special purpose British Columbia company incorporated solely for the purpose of the Financing and wholly-owned by […]
Havn Life Sciences Partners With Veterans Mental Health Non-Profit, Westwood Institute
Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (“Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce a partnership with the Westwood Institute (the “Institute”), a veterans mental health-focused non-profit founded by Dr. Marvin Westwood. The Institute’s mission is to […]
Field Trip Health Ltd. Provides Operational and Investor Update
Field Trip Health Ltd. (CSE: FTRP) (OTCBB: FTRPF) (“Field Trip”), a leader in the development and delivery of psychedelic therapies, is pleased to announce that, in response to significant interest from people and medical professionals in Canada, it is expanding the hours of operation at its Toronto Field Trip Health location to provide its psychedelic […]
Lobe Sciences Commences Engineering of Nasal Mist Device
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to announce that it has engaged VisionWorks Engineering of San Diego, CA to commence engineering work to complete and test a proof of concept prototype of its nasal mist device. This is a major milestone towards the ultimate goal for development […]
Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific
Vancouver, BC – December 4, 2020 – Entheon Biomedical Corp. (CSE: “ENBI”) (FSE:1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces a strategic investment in Wonder Scientific Inc. (“Wonder Scientific”). Wonder Scientific’s team of University Researchers and Product Development experts create custom, naturally derived, active pharmaceutical ingredients […]
First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder VANCOUVER, BC, Dec. 2, 2020 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, and the Multidisciplinary Association for Psychedelic […]
PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that it has amended its sponsored research agreement with University Health Network (“UHN”) for the development of panaceAI™, the Company’s drug […]
Havn Life Attracts International Drug Science and Policy Expert, Joins UK Policy Reform Group
Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (“Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has become a voting member of the Conservative Drug Policy Reform Group (CDPRG). The Company is also pleased to announce that David […]
Mind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure”) is pleased today to announce the appointment of Kelsey Ramsden as President and Chief Executive Officer, effective immediately. With Over 15 years founding, scaling and operating innovative businesses across several industries, Mrs. Ramsden has built multiple eight-figure companies from the ground up. She […]
Lobe Sciences Announces CAD$23,000,000 Sale of Cowlitz Cannabis Option to Ionic Brands Corp.
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe“) is pleased to announce that it has received and signed a non-binding letter of intent dated November 30, 2020 with IONIC Brands Corp. (“Ionic“) for the proposed sale to Ionic of certain assets held by Lobe related to Cowlitz County Cannabis Cultivation Inc. (“Cowlitz“) (the “Transaction“). […]
Pure Extracts Collaborates with Dr. Alexander MacGregor on Cannabis and Mushroom Formulations
December 02, 2020 09:00 ET | Source: Pure Extracts Technologies Corp. VANCOUVER, British Columbia, Dec. 02, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is pleased to provide an introduction to Dr. Alexander MacGregor, a […]
November 30, 2020 17:05 ET | Source: Field Trip Health, Ltd. Pre-clinical studies demonstrate potential of FT-104, its novel psychedelic molecule, as preferable option for psychedelic therapies, with comparable potency to psilocybin and shorter duration 4 Field Trip Health centers are in operation, with Amsterdam and newly announced locations in Atlanta, GA and Houston, TX under construction Digital […]
Nova Mentis Life Science Completes Acquisition of Pilz Bioscience
VANCOUVER, BC, Nov. 30, 2020 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that, further to its news releases dated November 2 and November 18, 2020, the amalgamation between Pilz Bioscience Corp. (“Pilz“) and 1271642 B.C. Ltd. (“Nova Subco“), a wholly-owned subsidiary of the Company, has been completed (the “Transaction“). Strategic and […]
Centre for Human Drug Research led DMT study to start in 2021 Vancouver, BC – December 1, 2020 – Entheon Biomedical Corp. (“Entheon” or the “Company”) (CSE: ENBI) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a Clinical Study Agreement with the Contract Research Organization (CRO) Centre […]
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC“) for the treatment of mild traumatic brain injury/concussion (“mTBI“) with post-traumatic stress disorder (“PTSD“). The study is in collaboration with a multidisciplinary team of scientists and physicians at […]
Pure Extracts Unveils Plans for Functional Mushrooms
There are more than 2,000 species of edible fungi and at least 15 have functional benefits that support overall health. Like other superfoods, functional mushrooms have antioxidant properties that support the immune system, dietary fiber to aid in healthy digestion and numerous other benefits to everything from mental clarity to skin health. At the […]
Pure Extracts Advances Plans for the Processing of Functional Mushroom Formulations
VANCOUVER, British Columbia, Nov. 26, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp . (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sectors, is pleased to provide an update and overview regarding its expansion into the functional mushroom wellness sector. […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace.
Headquartered in Calgary, Canada , Willow and its team of scientists are leaders in the field of biosynthetic production of high value plant-derived compounds.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
